Overall Score

Revenue Model

ARCT remains a non-dividend biotech with revenue generation still limited relative to valuation, as reflected by a 12.28x price-to-sales ratio and 5.19x EV/sales.

Gross margin is very strong at 83.2%, indicating the underlying product economics are attractive when revenue is recognized.

Profitability

Profitability remains deeply negative, with EBIT margin at -357.2%, operating margin at -433.4%, and net margin at -391.9%.

Returns on capital are still materially negative, including ROIC at -53.0% and ROE at -46.5%.

Financial Health

Liquidity remains strong with a current ratio of 5.88 and cash ratio of 5.71, supported by cash per share of 6.74.

Balance sheet leverage remains modest, with debt-to-equity at 0.13 and debt-to-assets at 0.10.

Cash Flow

Cash generation remains negative, with operating cash flow per share at -2.56 and free cash flow per share at -2.57.

Free cash flow yield is still negative at -25.0%, indicating ongoing cash burn.

Growth Scalability

The business shows some operating leverage potential, but current asset turnover is only 0.11 and working capital turnover is 0.14.

High R&D intensity at 362.1% of revenue suggests continued investment in pipeline development rather than near-term scalability.

Valuation

Valuation remains mixed: EV/sales is 5.19x and price-to-book is 1.70x, which is not extreme for a biotech platform but still requires future execution.

Negative earnings and cash flow keep traditional earnings-based valuation metrics from being meaningful.